175 related articles for article (PubMed ID: 2181072)
21. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
22. In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer.
Kim HJ; Heo DS; Suh CI; Kim HT; Bang YJ; Kim NK
Anticancer Res; 1995; 15(4):1247-55. PubMed ID: 7654004
[TBL] [Abstract][Full Text] [Related]
23. In vitro induction of perforin mRNA and cytotoxic activities in human splenocytes by the streptococcal preparation, OK-432.
Kataoka K; Naomoto Y; Orita K
Jpn J Clin Oncol; 1991 Oct; 21(5):330-3. PubMed ID: 1753412
[TBL] [Abstract][Full Text] [Related]
24. Generation of cytotoxic cells from murine bone marrow by human recombinant IL 2.
Koo GC; Manyak CL
J Immunol; 1986 Sep; 137(6):1751-6. PubMed ID: 2427580
[TBL] [Abstract][Full Text] [Related]
25. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
26. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
28. [A basic study of combination cancer immunotherapy with OK-432 and rIL-2--induction of lymphokine-activated killer (LAK) precursor cells in murine spleen by intravenous administration of OK-432].
Shimoda K; Saito T; Kobayashi M
Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1566-73. PubMed ID: 3263451
[No Abstract] [Full Text] [Related]
29. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
30. Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor.
Skornick Y; Topalian S; Rosenberg SA
J Biol Response Mod; 1990 Aug; 9(4):431-8. PubMed ID: 2395007
[TBL] [Abstract][Full Text] [Related]
31. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
Kaji R; Yoshida H; Yanagawa T; Sato M
J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
34. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
35. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of new-type recombinant interleukin-2.
Feng XS; Zheng XJ; Si QS; Lin YL; Chang Y; Fan PF; Yu JL; Zhang SR; Liu XY
Zhongguo Yao Li Xue Bao; 1992 Sep; 13(5):435-8. PubMed ID: 1300048
[TBL] [Abstract][Full Text] [Related]
37. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
39. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
40. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.
Yang JC; Perry-Lalley D; Rosenberg SA
J Biol Response Mod; 1990 Apr; 9(2):149-59. PubMed ID: 1971302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]